We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.
- Authors
Abdelmotilib, Hisham; West, Andrew B.
- Abstract
Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson's disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this twopronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.
- Subjects
PARKINSON'S disease treatment; LUNG diseases; ALPHA-synuclein; HISTONE acetylation; GENETIC transcription regulation
- Publication
Genome Medicine, 2017, Vol 9, p1
- ISSN
1756-994X
- Publication type
Article
- DOI
10.1186/s13073-017-0483-4